Exosome biomarkers for prediction and diagnosis of Parkinson’s Disease
Isolation of neuronal exosomes from blood allows for prediction of individuals who are likely to progress to PD, and differentiate those with PD from Parkinson’s-like diseases. Suitable for clinical trial recruitment.
Applications: Diagnostic, Biomarkers, Screening, Parkinson’s Disease
| Features | Benefits |
|---|---|
| Identification of the neuronal exosomes that contain clinically relevant information | Targeted exosome analysis removes confusion seen in many studies of α-synuclein as a biomarker |
| Two biomarkers that can be measured associated with PD – α-synuclein and Clusterin | Greater than 90% sensitivity and specificity in differentiation of PD, even in the prodromal phase |
| Biomarkers validated on large international cohorts | Strong evidence supporting the use of these biomarkers amongst three PD cohorts |
| Differentiate healthy controls from individuals with PD or will develop PD, and those with PD-like disease, tauopathies, non-α-synuclein proteinopathies | Diagnostic applications, Predictive applications, Screening applications, Suitable for clinical trial recruitment |
| Run using blood-based samples – whole blood, serum, plasma | Allows for rapid high throughput analysis and patient screening |